Understanding Dose Titration: Overactive Bladder Treatment With Fesoterodine as an Example

European Urology, Supplements

Volumn 10, Issue 1, 2011, Pages 8-13

  Michel, Martin C ^a   Staskin, David ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dose response; Fesoterodine; Muscarinic antagonists; Overactive bladder; Pharmacodynamic; Pharmacokinetic

Indexed keywords

FESOTERODINE; PLACEBO;

DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SENSITIVITY; DRUG TOLERABILITY; HUMAN; OVERACTIVE BLADDER; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

EID: 79251597131     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2011.01.004     Document Type: Review

References (34)

1. Abrams P., Artibani W., Gajewski J.B., Hussain I. Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology 2006, 68:17-28.
2. Chapple C.R., Khullar V., Gabriel Z., Muston D., Bitoun C.E., Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008, 54:543-562.
3. Michel M.C., Barendrecht M.M. Physiological and pathological regulation of the autonomic control of urinary bladder contractility. Pharmacol Ther 2008, 117:297-312.
4. Fenech A.G., Billington C.K., Swan C., et al. Novel polymorphisms influencing transcription of the human CHRM2 gene in airway smooth muscle. Am J Respir Cell Mol Biol 2004, 30:678-686.
5. Ancelin M.L., Artero S., Portet F., Dupuy A.M., Touchon J., Ritchie K. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006, 332:455-459.
6. Franco-Salinas G., de la Rosette J.J., Michel M.C. Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations. Clin Pharmacokinet 2010, 49:177-188.
7. Matsushima H., Kamimura H., Soeishi Y., Watanabe T., Higuchi S., Tsunoo M. Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and humans. Drug Metab Dispos 1998, 26:240-245.
8. Kay G., Malhotra B., Michel M. Assessment of central nervous system access of a new antimuscarinic drug, fesoterodine. J Urol 2010, 181:84.
9. Zanger U.M., Raimundo S., Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004, 369:23-37.
10. Skerjanec A. The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet 2006, 45:325-350.
11. Guay D.R. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet 2003, 42:1243-1285.
12. Witte L.P., Mulder W.M., de la Rosette J.J., Michel M.C. Muscarinic receptor antagonists for overactive bladder treatment: does one fit all?. Curr Opin Urol 2009, 19:13-19.
13. Benner J.S., Nichol M.B., Rovner E.S., et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 2009, 105:1276-1282.
14. Schneider T., Hein P., Michel-Reher M.B., Michel M.C. Effects of ageing on muscarinic receptor subtypes and function in rat urinary bladder. Naunyn Schmiedebergs Arch Pharmacol 2005, 372:71-78.
15. Abrams P., Andersson K.E., Buccafusco J.J., et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006, 148:565-578.
16. Taylor A.A., Pool J.L. Clinical pharmacology of antihypertensive therapy. Semin Nephrol 2005, 25:215-226.
17. Ruhe H.G., Booij J., v Weert H.C., et al. Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology 2009, 34:999-1010.
18. Malhotra B., Gandelman K., Sachse R., Wood N., Michel M.C. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem 2009, 16:4481-4489.
19. Diefenbach K., Jaeger K., Wollny A., Penzel T., Fietze I., Roots I. Effect of tolterodine on sleep structure modulated by CYP2D6 genotype. Sleep Med 2008, 9:579-582.
20. Michel M.C. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 2008, 9:1787-1796.
21. Malhotra B, Crownover P, LaBadie R, Glue P. Pharmacokinetic variability is lower following administration of fesoterodine compared with tolterodine. Abstract presented at: Annual Meeting of the International Continence Society; 29 September-3 October 2009; San Francisco, CA, USA.
22. Malhotra B., Guan Z., Wood N., Gandelman K. Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther 2008, 46:556-563.
23. Malhotra B., Sachse R., Wood N. Influence of food on the pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther 2009, 47:384-390.
24. Malhotra B.K., Wood N., Sachse R. Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. Int J Clin Pharmacol Ther 2009, 47:570-578.
25. Malhotra B.K., Crownover P.H., LaBadie R., Glue P., MacDiarmid S.A. The pharmacokinetic profile of fesoterodine 8mg with daytime or nighttime dosing. Eur J Clin Pharmacol 2010, 66:171-176.
26. Malhotra B., Gandelman K., Sachse R., Wood N. Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine. J Clin Pharmacol 2009, 49:477-482.
27. deMey C, Maleva L, Kraslev Z, Sachse R, Wood N, Malhotra B. Effects of hepatic dysfunction on the single-dose pharmacokinetics of fesoterodine. J Clin Pharmacol. In press. doi:10.1177/0091270010365547.
28. Khullar V., Rovner E.S., Dmochowski R., Nitti V., Wang J., Guan Z. Fesoterodine dose response in subjects with overactive bladder syndrome. Urology 2008, 71:839-843.
29. Chapple C., Vonkeman H., Hellmis E., Al-Shukri S., Arpo H. Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase 2 controlled study. Neurourol Urodyn 2004, 23:598-599.
30. Nitti V, Viatrak M, Kreitman L, Lipsitz D. Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial. Abstract presented at: Annual Meeting of the International Continence Society; 28 August-2 September 2005; Montreal, Canada.
31. Wyndaele J.J., Goldfischer E.R., Morrow J.D., et al. Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. Int J Clin Pract 2009, 63:560-567.
32. Dmochowski R.R., Peters K.M., Morrow J.D., et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. Urology 2010, 75:62-68.
33. Bodeker R.H., Madersbacher H., Neumeister C., Zellner M. Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence. BMC Urol 2010, 10:15.
34. Cardozo L., Khullar V., El-Tahtawy A., Guan Z., Malhotra B., Staskin D. Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder. BMC Urol 2010, 10:14.